GlycoMimetics focuses on therapies for cancers and inflammatory diseases in the US. It develops uproleselan to treat acute myeloid leukemia (AML) with chemotherapy. The company completed a phase 3 trial for relapsed/refractory AML. Other programs include GMI-1687 for vaso-occlusive crisis and GMI-2093 for galectin-3. Its portfolio also includes GMI-1359 targeting e-selectin and chemokine receptor for osteosarcoma treatment. The company has a research agreement with the National Cancer Institute and a collaboration with Apollomics (Hong Kong) Limited. GlycoMimetics was incorporated in 2003 and is headquartered in Rockville, Maryland.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 0.4 |